Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.75 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | STAT3 | P40763 | 1/20 | 0.56 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.55 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | BRAF | P15056 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25668858 | 0.86 | SMN1; SMN2 (1.00) | SMN1; SMN2TDP1ALDH1A1MEN1KMT2A | |
| SCHEMBL18387929 | 0.85 | SMN1; SMN2 (0.78) | SMN1; SMN2TDP1LMNAALDH1A1MEN1 | |
| SCHEMBL25668516 | 0.82 | SMN1; SMN2 (0.73) | SMN1; SMN2TDP1LMNAALDH1A1MEN1 | |
| SCHEMBL1397448 | 0.82 | GAA (0.55) | SMN1; SMN2TDP1LMNAALDH1A1POLB | |
| SCHEMBL29503163 | 0.82 | GAA (0.55) | SMN1; SMN2TDP1LMNAALDH1A1POLB | |
| SCHEMBL15987037 | 0.79 | SMN1; SMN2 (0.68) | SMN1; SMN2TDP1LMNAALDH1A1MEN1 | |
| SCHEMBL14501007 | 0.79 | SMN1; SMN2 (0.68) | SMN1; SMN2LMNAALDH1A1MEN1KMT2A | |
| SCHEMBL2566373 | 0.78 | SMN1; SMN2 (0.67) | SMN1; SMN2TDP1LMNAALDH1A1MEN1 | |
| SCHEMBL6153699 | 0.78 | PTGS1 (0.67) | SMN1; SMN2TDP1LMNAALDH1A1MEN1 | |
| SCHEMBL23677225 | 0.77 | SMN1; SMN2 (0.70) | SMN1; SMN2TDP1LMNAALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050182040-A1 | Benzamide derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
| EP-1500643-A1 | BENZAMIDE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2005-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182040-A1 | Benzamide derivatives | ROCK1, ROCK2, NHERF1 | SMN1; SMN2 3598/4885TDP1 3782/4885LMNA 1200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.